CBIH Ignites Texas: Statewide TCUP Seminar Marks a New Era for Medical Cannabis-With Evidence, Safety, and Patient Dignity at the Center

Cannabis Bioscience International Holdings, Inc. Appoints Veteran Financier Andy Trivedi to Its Board of Directors, Strengthening Capital Strategy and Growth Outlook

CBIH Announces Women-First Fertility Innovation Built on Nanoemulsion Delivery

CBIH: Potential Rescheduling to Schedule III Could Reward Decades of Scientific Preparation and Regulatory Discipline

CBIH Welcomes Federal Momentum Toward Cannabis Rescheduling as 2026 Opens a New Window to Accelerate Medical Innovation and Growth, with CBIH Positioned to Capitalize on Emerging Opportunities

CBIH Announces New Patent Initiative Targeting Opioid Addiction Through Endocannabinoid Pathways

CBIH Launches Federal and Pharmaceutical Outreach Initiative to Accelerate Medical Cannabis Research in the Schedule III Transition

CBIH Puts CMS at the Center of the Board: Formal Coordination with Dr. Mehmet Oz's Team and an "Evidence Sprint 2026" Focused on Grants, Research and Clinical Evidence

CBIH Evaluates a Potential Reg A Offering of Approximately $1,000,000 to Enable Commercial Launch, Statewide Educational Expansion, and Protection of Its Patent Portfolio

CBIH Completes Cannabinoid-Based Melanoma Patent Application Program Focused on Cannabinoid Science and Epigenetic Regulation